公司概述
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical entity dedicated to the development, manufacture, and commercialization of therapeutic solutions specifically designed for patients suffering from cancer. The company positions itself within the broader Healthcare sector, focusing its operational activities on the specialized Biotechnology industry where innovation in radiotherapeutic candidates is critical. In terms of scale, the firm maintains a market capitalization of $21.75M, reports trailing twelve-month revenue of $5.21M, and employs a workforce of 28 individuals. These financial metrics indicate that Plus Therapeutics is a small-cap entity with limited revenue generation relative to its valuation, suggesting a position typical for early-stage clinical companies that have not yet achieved commercial profitability or significant market penetration.
财务健康
The company reported trailing twelve-month revenue of $5.21M alongside a net income of $-22,386,000 and an EBITDA of $-14,853,000, highlighting a substantial gap between top-line revenue and bottom-line earnings that reveals a high-cost structure inherent to clinical-stage development phases. Free cash flow stands at $-13,597,750, indicating that the company is currently consuming cash reserves to fund its operations and research activities rather than generating liquidity. The margin analysis shows a gross margin of -60.7%, an operating margin of -420.0%, and a profit margin of 0.0%, collectively indicating significant cost pressures relative to sales and a complete lack of profitability at the current operational level. Regarding liquidity and leverage, the company holds $8.61M in cash against $821,000 in debt, supported by a debt-to-equity ratio of 20.55 and a current ratio of 1.23. While the current ratio of 1.23 suggests the company possesses sufficient short-term assets to cover its liabilities, the negative return on equity and return on assets of -83.3% reveal that management effectiveness in generating returns on capital is severely compromised by ongoing losses.
估值评估
Valuation metrics for Plus Therapeutics present a complex picture with a P/E ratio (TTM) listed as N/A due to negative earnings and a forward P/E of -1.41, implying that traditional earnings-based valuation models are currently inapplicable and that the market is pricing in future earnings potential rather than current profitability. The price-to-book ratio is calculated at 4.40, which indicates that the market is valuing the company at a significant premium over its book value, likely reflecting expectations regarding the potential success of its lead radiotherapeutic candidate, rhenium obisbemeda. Alternative valuation measures include a price-to-sales ratio of 4.17 and an EV/EBITDA of -0.94, suggesting the market is willing to pay a high multiple of sales for a company that is currently unprofitable and has negative enterprise value relative to earnings. The stock's trading range over the past year spans from a 52-week low of $3.01 to a 52-week high of $30.50, placing the current market sentiment in a highly volatile environment where price discovery is difficult without fundamental earnings support. The beta value of 1.02 indicates that the stock's price volatility moves in tandem with the broader market, lacking significant defensive characteristics or excessive aggression relative to the index.
Growth & Income
Revenue growth year-over-year is recorded at -3.2% while earnings growth is listed as N/A, implying that the company is currently contracting in terms of top-line sales and is not yet generating positive earnings to track against revenue changes. As a non-dividend payer, the company does not distribute a dividend yield or utilize a payout ratio, meaning that any available cash flow is theoretically retained for reinvestment into research and development rather than being distributed to shareholders. This reinvestment strategy is characteristic of clinical-stage biotechnology firms that prioritize advancing their drug pipeline, such as the development of rhenium obisbemeda, over providing immediate income to investors. The overall growth and income profile is defined by negative revenue momentum, zero dividend income, and a reliance on cash reserves to sustain operations until a potential future commercial milestone is achieved.